IP Library Patent Application 16138940
Patent Application
App. No. 16/138,940

CELL COMPOSITION AND METHODS OF MAKING THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/138,940
Abstract

Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.

Claims (14)

1 - 28 . (canceled)

29 . A composition comprising a plurality of isolated human adherent placental cells in a solution comprising 10% dextran 40, wherein said composition comprises between about 1.0±0.3×106 cells per milliliter to about 5.0±1.5×106 cells per milliliter, and wherein said composition comprises no macro cell clumps.

30 . The composition of claim 29 , wherein said placental stem cells are thawed cryopreserved cells.

31 . The composition of claim 29 , wherein said composition is contained within a bag.

32 . The composition of claim 29 , wherein said composition comprises no macro cell clumps.

33 . The composition of claim 29 , wherein said composition comprises fewer than about 200 micro cell clumps per 106 cells.

34 . The composition of claim 29 , wherein said composition comprises fewer than about 150 micro cell clumps per 106 cells.

35 . The composition of claim 29 , wherein said composition comprises fewer than about 100 micro cell clumps per 106 cells.

36 . The composition of claim 29 , wherein said isolated human adherent placental cells are CD10+, CD34− and CD105+.

37 . The composition of claim 36 , wherein said CD10+, CD34− and CD105+ cells are CD200+.

38 . The composition of claim 37 , wherein said CD10+, CD34−, and CD105+ and CD200+ cells are either CD45− or CD90+.

39 . The composition of claim 37 , wherein said CD10+, CD34−, and CD105+ and CD200+ cells are CD45− or CD90+.

40 . The composition of claim 29 , wherein said composition is a pharmaceutical composition.

41 - 42 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2023
From: CLARITY ACQUISITION II LLC
To: CELULARITY INC.
Reel/Frame 062881/0570 →